SCHEMBL10330700

SCHEMBL10330700

COC(=O)c1cc2ccc(NCC(O)CO)nc2[nH]c1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.37
▸ GLA P06280 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ IRAK4 Q9NWZ3 1/20 0.36
▸ PRKDC P78527 1/20 0.36
▸ CNR2 P34972 2/20 0.35
▸ DYRK1A Q13627 2/20 0.34
▸ DYRK1B Q9Y463 2/20 0.34
▸ CYP1A2 P05177 4/20 0.33
▸ SLC2A1 P11166 1/20 0.33
▸ CA12 O43570 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA3 P07451 1/20 0.33
▸ CA6 P23280 1/20 0.33
▸ CA5A P35218 1/20 0.33
▸ CA7 P43166 1/20 0.33
▸ CA9 Q16790 1/20 0.33
▸ CA14 Q9ULX7 1/20 0.33
▸ CA5B Q9Y2D0 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10320968 0.87 PRKDC (0.38) KDM4EGAAIRAK4PRKDCCNR2
SCHEMBL10321581 0.72 KDM4E (0.46) KDM4EGLAGAACNR2DYRK1A
SCHEMBL10321486 0.72 CLK1 (0.47) KDM4EGLAGAACNR2DYRK1A
SCHEMBL10322166 0.71 BUB1 (0.38) KDM4EGLAGAADYRK1ADYRK1B
SCHEMBL10322470 0.68 RAB9A (0.43) DYRK1ADYRK1BALDH1A1KMT2ASMN1; SMN2
SCHEMBL10322787 0.68 DYRK1A (0.68) DYRK1ADYRK1B
SCHEMBL30549017 0.67 DAO (0.59) KDM4EGLAGAAALDH1A1
SCHEMBL589427 0.65 ALDH1A1 (0.56) KDM4EGAAALDH1A1KMT2A
SCHEMBL10320554 0.65 KDM4E (0.51) KDM4EGLAGAACYP1A2ALDH1A1
SCHEMBL155989 0.65 PRKDC (0.42) IRAK4PRKDCCYP1A2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012098066-A1 1,6- AND 1,8-NAPHTHYRIDINES USEFUL AS DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — WO disclosed
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES LUK KIN-CHUN (US) 2012-07-19 — — US disclosed
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES LUK KIN-CHUN (US) 2012-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES PSEN1, BRCA1, PSEN2 KDM4E 2930/4885GLA 150/4885GAA 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback